Phase I and I/II clinical trials are ongoing at AIM ImmunoTech (formerly HemispheRx) to evaluate its vaccine adjuvant potential for the treatment of stage II–IV HER2+ breast cancer, triple-negative breast cancer, and several other solid tumors, such as renal cell carcinoma, pancreatic cancer, and ovarian cancer. The gene discussed is ERBB2; the disease is breast cancer.